Seroatlas · Human Serome Atlas

PRAMEF2

PRAME family member 2

Also known as: FLJ43580, PRAM2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O60811
Gene: PRAMEF2
Ensembl: ENSG00000120952
Chromosome: 1
Canonical length: 474 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

Predicted to enable ubiquitin-like ligase-substrate adaptor activity. Predicted to be involved in proteasome-mediated ubiquitin-dependent protein catabolic process. Predicted to be part of Cul2-RING ubiquitin ligase complex. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

474 residues, UniProt reviewed canonical sequence.

>O60811|PRAMEF2
     1  MSIQAPPRLL ELAGQSLLRD QALSISAMEE LPRVLYLPLF REAFSRRHFQ TLTVMVQAWP
    61  FTCLPLVSLM KTLHLEPLKA LLEGLHMLLT QKDRPRRWKL QVLDLRDVDE NFWARWPGAW
   121  ALSCFPEAMS KRQTAEDCPR TGEHQPLKVF IDICLKEIPQ DECLRYLFQW VYQRRGLVHL
   181  CCSKLVNYLT PIKYLRKSLK IIYINSIGEL EIHNTCWPHL IRKLYCYLKE MKTLCKLVFS
   241  RCHHYTSDNE LEGWLVTRFT SVFLRLEHLQ LLKIKLITFF SGHLEQLIRC LQNPLENLEL
   301  TCGNLLEEDL KCLSQFPSLG YLKHLNLSYV LLFRISLEPL GALLEKIAAS LETLVLEGCQ
   361  IHYSQLSAIL PGLSCCSQLT TFYFGSNCMS IDALKDLLRH TSGLSKLSLE TYPAPEESLN
   421  SLVRVNWEIF TPLRAELMCT LREFRQPKRI FIGPTPCPSC GSSPSEELEL HLCC

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRAMEF2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.28
Highest tissue expression: 0.2 nTPM

Expression across tissuesHPA

Tissue

testis: 0.2 nTPM
adipose tissue: 0 nTPM
adrenal gland: 0 nTPM
amygdala: 0 nTPM
appendix: 0 nTPM
basal ganglia: 0 nTPM

Single-cell type

adipocytes: 0 nCPM
adrenal cortex cells: 0 nCPM
adrenal medulla cells: 0 nCPM
alveolar cells type 1: 0 nCPM
alveolar cells type 2: 0 nCPM
astrocytes: 0 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

amygdala: 0 nTPM
basal ganglia: 0 nTPM
cerebellum: 0 nTPM
cerebral cortex: 0 nTPM
choroid plexus: 0 nTPM
hippocampal formation: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.81
gnomAD pLI: 0
gnomAD missense Z: -3.95
DepMap mean gene effect: -0.01
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

ubiquitin-like ligase-substrate adaptor activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRAMEF2 as an antibody target. Whether an autoantibody or antibody against PRAMEF2 could matter depends on whether native PRAMEF2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRAMEF2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PRAMEF2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...